Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Am J Hum Genet ; 108(7): 1217-1230, 2021 07 01.
Artigo em Inglês | MEDLINE | ID: mdl-34077760

RESUMO

Genome-wide association studies (GWASs) require accurate cohort phenotyping, but expert labeling can be costly, time intensive, and variable. Here, we develop a machine learning (ML) model to predict glaucomatous optic nerve head features from color fundus photographs. We used the model to predict vertical cup-to-disc ratio (VCDR), a diagnostic parameter and cardinal endophenotype for glaucoma, in 65,680 Europeans in the UK Biobank (UKB). A GWAS of ML-based VCDR identified 299 independent genome-wide significant (GWS; p ≤ 5 × 10-8) hits in 156 loci. The ML-based GWAS replicated 62 of 65 GWS loci from a recent VCDR GWAS in the UKB for which two ophthalmologists manually labeled images for 67,040 Europeans. The ML-based GWAS also identified 93 novel loci, significantly expanding our understanding of the genetic etiologies of glaucoma and VCDR. Pathway analyses support the biological significance of the novel hits to VCDR: select loci near genes involved in neuronal and synaptic biology or harboring variants are known to cause severe Mendelian ophthalmic disease. Finally, the ML-based GWAS results significantly improve polygenic prediction of VCDR and primary open-angle glaucoma in the independent EPIC-Norfolk cohort.


Assuntos
Aprendizado de Máquina , Disco Óptico/anatomia & histologia , Conjuntos de Dados como Assunto , Angiofluoresceinografia , Estudo de Associação Genômica Ampla , Glaucoma de Ângulo Aberto/diagnóstico por imagem , Humanos , Modelos Anatômicos , Disco Óptico/diagnóstico por imagem , Fenótipo , Medição de Risco
2.
Commun Biol ; 4(1): 1269, 2021 11 05.
Artigo em Inglês | MEDLINE | ID: mdl-34741098

RESUMO

There is currently a dearth of accessible whole genome sequencing (WGS) data for individuals residing in the Americas with Sub-Saharan African ancestry. We generated whole genome sequencing data at intermediate (15×) coverage for 2,294 individuals with large amounts of Sub-Saharan African ancestry, predominantly Atlantic African admixed with varying amounts of European and American ancestry. We performed extensive comparisons of variant callers, phasing algorithms, and variant filtration on these data to construct a high quality imputation panel containing data from 2,269 unrelated individuals. With the exception of the TOPMed imputation server (which notably cannot be downloaded), our panel substantially outperformed other available panels when imputing African American individuals. The raw sequencing data, variant calls and imputation panel for this cohort are all freely available via dbGaP and should prove an invaluable resource for further study of admixed African genetics.


Assuntos
Genoma Humano , Genótipo , Adulto , Negro ou Afro-Americano , Idoso , Idoso de 80 Anos ou mais , Humanos , Pessoa de Meia-Idade , Estados Unidos , Sequenciamento Completo do Genoma , Adulto Jovem
3.
Pharmacogenomics ; 16(3): 227-37, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25712186

RESUMO

AIM: The limited formal study of the clinical feasibility of implementing pharmacogenomic tests has thus far focused on providers at large medical centers in urban areas. Our research focuses on small metropolitan, rural and tribal practice settings. MATERIALS & METHODS: We interviewed 17 healthcare providers in western Montana regarding pharmacogenomic testing. RESULTS: Participants were optimistic about the potential of pharmacogenomic tests, but noted unique barriers in small and rural settings including cost, adherence, patient acceptability and testing timeframe. Participants in tribal settings identified heightened sensitivity to genetics and need for community leadership approval as additional considerations. CONCLUSION: Implementation differences in small metropolitan, rural and tribal communities may affect pharmacogenomic test adoption and utilization, potentially impacting many patients. Original submitted 3 September 2014; Revision submitted 3 December 2014.


Assuntos
Farmacogenética/tendências , Adulto , Feminino , Serviços de Saúde do Indígena , Humanos , Indígenas Norte-Americanos , Masculino , Pessoa de Meia-Idade , Montana , Padrões de Prática Médica/tendências , Medicina de Precisão , Serviços de Saúde Rural
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA